rss
Br J Ophthalmol 2007;91:804-807 doi:10.1136/bjo.2006.107912
  • Laboratory science - Scientific reports

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

  1. Roberta P A Manzano1,2,
  2. Gholam A Peyman1,
  3. Palwasha Khan1,
  4. Petros E Carvounis1,
  5. Muhamet Kivilcim3,
  6. Min Ren1,
  7. Jonathan C Lake2,
  8. Patricia Chévez-Barrios1
  1. 1Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
  2. 2Department of Ophthalmology, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
  3. 3Department of Ophthalmology, University of Arizona, Arizona Health Sciences Center, Tucson, Arizona, USA
  1. Correspondence to: Dr G A Peyman Department of Ophthalmology, University of Arizona, 655 N Alvernon Way, Ste 108, Tucson, AZ 85711, USA; ccole{at}eyes.arizona.edu
  • Accepted 9 December 2006
  • Published Online First 19 December 2006

Abstract

Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats.

Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area.

Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann–Whitney U test).

Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

Footnotes

  • Published Online First 19 December 2006

  • Competing interests: None.

Responses to this article

  • Bevacizumab and rodent VEGF
    • Jing Hua,
    • Alex H. R. Varey, David O. Bates
    Br J Ophthalmol published online August 4, 2009
  • Use of Avastin in rat models: Comments.
    • Yuksel Totan,
    • Mesut Erdurmus
    Br J Ophthalmol published online August 4, 2009

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2006.107912v1
    2. 91/6/804 most recent

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.